Heft Nr. 5/2026
Anzeigenschluss: 20.04.2026
Erscheinungstermin: 18.05.2026
Dermatoonkologie
Schwerpunkt
Melanom
Drummer R et al.
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Melanom
Mundada M et al.
Clinical and Pathologic Factors in Stage I and II Melanoma Recurrence
Melanom
Okwara CJ et al.
Diagnostic Accuracy of Dermoscopic Features in Acral Lentiginous Melanoma. A Systematic Review and Meta-analysis
Melanom
Marjanovic M et al.
Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma: A Nationwide Population-Based Registry Study from Sweden
Gynäkoonkologie
Brustkrebs
Peccatori FA et al.
Lactation in survivors of hormone receptor–positive breast cancer who temporarily interrupted endocrine therapy to attempt pregnancy: results from the POSITIVE trial
Zervixkarzinom
Ryu SY et al.
Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008
Pneumoonkologie
NSCLC
Fang W et al.
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
NSCLC
Bradley JD et al.
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
NSCLC
Wu YL et al.
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
Kongressbericht
DGHO-Frühjahrstagung
Kongressbericht
Kongress der Deutschen Gesellschaft für Pneumologie
Gastroonkologie
GEP-NET
Xu J et al.
Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1 – 2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
Kolorektalkarzinom
Lepage C et al.
Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial
Ösophaguskarzinom
Metges JP et al.
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III Keynote-590 study
Allgemeine Onkologie
Irinotecan-Dosierung
Peeters SLJ et al.
Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017 – 2024): a retrospective, multicentre cohort study
PZO
Patientenschulungen – PEAK-Akademie
Kongressbericht
ESMO Sarcoma and Rare Cancers Congress 2026
Uroonkologie
RCC
Motzer RJ et al.
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial
Blasenkarzinom
Roupret M et al.
ALBAN (GETUG-AFU 37): A phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
Hämatologie
Multiples Myelom
Manier S et al.
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
Multiples Myelom
Costa LJ et al.
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
DLBCL
Budde LE et al.
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
*Die Redaktion behält sich aktuelle Änderungen vor.